Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGAM | O43451 | 1/20 | 0.60 |
| ▸ | PTPN1 | P18031 | 8/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | TTR | P02766 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | TYR | P14679 | 1/20 | 0.48 |
| ▸ | BCHE | P06276 | 2/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | PDE2A | O00408 | 1/20 | 0.39 |
| ▸ | PDE5A | O76074 | 1/20 | 0.39 |
| ▸ | PDE9A | O76083 | 1/20 | 0.39 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.39 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.39 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Daleformis SCHEMBL21400795 | 1.00 | MGAM (0.60) | MGAMPTPN1NPC1HSP90AA1RAB9A | |
| Shinpterocarpin SCHEMBL29377666 | 0.79 | MGAM (0.77) | MGAMPTPN1NPC1HSP90AA1RAB9A | |
| Shinpterocarpin SCHEMBL30001940 | 0.79 | MGAM (0.77) | MGAMPTPN1NPC1HSP90AA1RAB9A | |
| Phaseolin SCHEMBL29351585 | 0.75 | MGAM (1.00) | MGAMPTPN1NPC1HSP90AA1RAB9A | |
| Phaseolin SCHEMBL33735 | 0.75 | MGAM (1.00) | MGAMPTPN1NPC1HSP90AA1RAB9A | |
| Phaseolin SCHEMBL29929606 | 0.75 | MGAM (1.00) | MGAMPTPN1NPC1HSP90AA1RAB9A | |
| Phaseolin SCHEMBL33736 | 0.75 | MGAM (1.00) | MGAMPTPN1NPC1HSP90AA1RAB9A | |
| Phaseolin SCHEMBL28856370 | 0.74 | MGAM (0.98) | MGAMPTPN1NPC1HSP90AA1RAB9A | |
| Phaseolin SCHEMBL28201435 | 0.71 | MGAM (0.90) | MGAMPTPN1NPC1HSP90AA1RAB9A | |
| Phaseolin SCHEMBL28209786 | 0.70 | MGAM (0.89) | MGAMPTPN1NPC1HSP90AA1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030176356-A1 | Endothelin antagonists and endothelin-converting enzyme inhibitors for the treatment of glaucoma | UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER | 2003-09-18 | — | — | US | claimed |
| EP-3774819-B1 | NOVEL HETEROCYCLIC SYSTEMS AND PHARMACEUTICAL COMPOSITIONS THEREOF | UNIV OF SHARJAH (AE) | 2025-07-30 | — | — | EP | disclosed |
| US-12157745-B2 | Heterocyclic systems and pharmaceutical compositions thereof | UNIVERSITY OF SHARJAH (AE) | 2024-12-03 | — | — | US | disclosed |
| US-12102653-B2 | Ligand regulated protein-protein interaction system | ST. ANNA KINDERKREBSFORSCHUNG (AT) | 2024-10-01 | — | — | US | disclosed |
| US-20240000841-A1 | LIGAND REGULATED PROTEIN-PROTEIN INTERACTION SYSTEM | ST ANNA KINDERKREBSFORSCHUNG (AT) | 2024-01-04 | — | — | US | disclosed |
| US-11844813-B2 | Ligand regulated protein-protein interaction system | ST. ANNA KINDERKREBSFORSCHUNG (AT) | 2023-12-19 | — | — | US | disclosed |
| US-20220041687-A1 | A GROUP OF CHIMERIC ANTIGEN RECEPTORS (CARS) | ST. ANNA KINDERKREBSFORSCHUNG (AT) | 2022-02-10 | — | — | US | disclosed |
| US-20210386781-A1 | A GROUP OF CHIMERIC ANTIGEN RECEPTORS (CARS) | UNIVERSITÄT FÜR BODENKULTUR WIEN (AT) | 2021-12-16 | — | — | US | disclosed |
| EP-3860643-A1 | A GROUP OF CHIMERIC ANTIGEN RECEPTORS (CARS) | St. Anna Kinderkrebsforschung (AT) | 2021-08-11 | — | — | EP | disclosed |
| EP-3860642-A1 | A GROUP OF CHIMERIC ANTIGEN RECEPTORS (CARS) | St. Anna Kinderkrebsforschung (AT) | 2021-08-11 | — | — | EP | disclosed |
| US-20210221825-A1 | NOVEL HETEROCYCLIC SYSTEMS AND PHARMACEUTICAL COMPOSITIONS THEREOF | UNIVERSITY OF SHARJAH (AE) | 2021-07-22 | — | — | US | disclosed |
| EP-3774819-A2 | NOVEL HETEROCYCLIC SYSTEMS AND PHARMACEUTICAL COMPOSITIONS THEREOF | University of Sharjah (AE) | 2021-02-17 | — | — | EP | disclosed |
| US-20200390813-A1 | LIGAND REGULATED PROTEIN-PROTEIN INTERACTION SYSTEM | ST. ANNA KINDERKREBSFORSCHUNG (AT) | 2020-12-17 | — | — | US | disclosed |
| EP-3728306-A1 | LIGAND REGULATED PROTEIN-PROTEIN INTERACTION SYSTEM | St. Anna Kinderkrebsforschung (AT) | 2020-10-28 | — | — | EP | disclosed |
| WO-2020070289-A1 | A GROUP OF CHIMERIC ANTIGEN RECEPTORS (CARS) | ST. ANNA KINDERKREBSFORSCHUNG (AT) | 2020-04-09 | — | — | WO | disclosed |
| WO-2020070290-A1 | A GROUP OF CHIMERIC ANTIGEN RECEPTORS (CARS) | ST. ANNA KINDERKREBSFORSCHUNG (AT) | 2020-04-09 | — | — | WO | disclosed |
| WO-2019186384-A2 | NOVEL HETEROCYCLIC SYSTEMS AND PHARMACEUTICAL COMPOSITIONS THEREOF | UNIVERSITY OF SHARJAH (AE) | 2019-10-03 | — | — | WO | disclosed |
| US-20190292204-A1 | NOVEL HETEROCYCLIC SYSTEMS AND PHARMACEUTICAL COMPOSITIONS THEREOF | UNIVERSITY OF SHARJAH (AE) | 2019-09-26 | — | — | US | disclosed |
| EP-3502130-A1 | LIGAND REGULATED PROTEIN-PROTEIN INTERACTION SYSTEM | St. Anna Kinderkrebsforschung (AT) | 2019-06-26 | — | — | EP | disclosed |
| US-20030176356-A1 | Endothelin antagonists and endothelin-converting enzyme inhibitors for the treatment of glaucoma | UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER | 2003-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12157745-B2 | Heterocyclic systems and pharmaceutical compositions thereof | FPGS, TXNRD1, FOLH1 | MGAM 813/4885PTPN1 2374/4885NPC1 2570/4885 |
| US-20030176356-A1 | Endothelin antagonists and endothelin-converting enzyme inhibitors for the treatment of glaucoma | ECE1, EDNRA, ECE2 | MGAM 2326/4885PTPN1 3845/4885NPC1 1536/4885 |
| US-20210221825-A1 | NOVEL HETEROCYCLIC SYSTEMS AND PHARMACEUTICAL COMPOSITIONS THEREOF | FPGS, TXNRD1, TXNRD3 | MGAM 863/4885PTPN1 2747/4885NPC1 2828/4885 |
| US-20220041687-A1 | A GROUP OF CHIMERIC ANTIGEN RECEPTORS (CARS) | CARS1, CD74, HAVCR2 | MGAM 2470/4885PTPN1 1563/4885NPC1 3227/4885 |
| US-20190292204-A1 | NOVEL HETEROCYCLIC SYSTEMS AND PHARMACEUTICAL COMPOSITIONS THEREOF | FPGS, TXNRD1, TXNRD3 | MGAM 863/4885PTPN1 2747/4885NPC1 2828/4885 |
| US-20210386781-A1 | A GROUP OF CHIMERIC ANTIGEN RECEPTORS (CARS) | CD74, HAVCR2, CD2BP2 | MGAM 1901/4885PTPN1 1140/4885NPC1 3403/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.